nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—L-Phenylalanine—Melphalan—peripheral nervous system neoplasm	0.676	1	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—TH—peripheral nervous system neoplasm	0.00373	0.692	CrCbGaD
Lisdexamfetamine—Lisinopril—ABCB1—peripheral nervous system neoplasm	0.00106	0.197	CrCbGaD
Lisdexamfetamine—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.000667	0.00211	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000667	0.00211	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000665	0.0021	CcSEcCtD
Lisdexamfetamine—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000664	0.0021	CcSEcCtD
Lisdexamfetamine—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.00066	0.00209	CcSEcCtD
Lisdexamfetamine—Eye disorder—Etoposide—peripheral nervous system neoplasm	0.000659	0.00208	CcSEcCtD
Lisdexamfetamine—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000657	0.00208	CcSEcCtD
Lisdexamfetamine—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000655	0.00207	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000654	0.00207	CcSEcCtD
Lisdexamfetamine—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000654	0.00207	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000642	0.00203	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.000637	0.00201	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000636	0.00201	CcSEcCtD
Lisdexamfetamine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.000632	0.002	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000629	0.00199	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000629	0.00199	CcSEcCtD
Lisdexamfetamine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000628	0.00199	CcSEcCtD
Lisdexamfetamine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000626	0.00198	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000624	0.00197	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000624	0.00197	CcSEcCtD
Lisdexamfetamine—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000623	0.00197	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.00062	0.00196	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000618	0.00196	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000616	0.00195	CcSEcCtD
Lisdexamfetamine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000613	0.00194	CcSEcCtD
Lisdexamfetamine—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000612	0.00193	CcSEcCtD
Lisdexamfetamine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000608	0.00192	CcSEcCtD
Lisdexamfetamine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000608	0.00192	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000607	0.00192	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000602	0.0019	CcSEcCtD
Lisdexamfetamine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.0006	0.0019	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.000598	0.00189	CcSEcCtD
Lisdexamfetamine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000597	0.00189	CcSEcCtD
Lisdexamfetamine—Selegiline—ABCB1—peripheral nervous system neoplasm	0.000597	0.111	CrCbGaD
Lisdexamfetamine—Anorexia—Vincristine—peripheral nervous system neoplasm	0.00059	0.00186	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000584	0.00185	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.000583	0.00184	CcSEcCtD
Lisdexamfetamine—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000581	0.00184	CcSEcCtD
Lisdexamfetamine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000581	0.00184	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000579	0.00183	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000579	0.00183	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000572	0.00181	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000572	0.00181	CcSEcCtD
Lisdexamfetamine—Diplopia—Epirubicin—peripheral nervous system neoplasm	0.000571	0.00181	CcSEcCtD
Lisdexamfetamine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000571	0.0018	CcSEcCtD
Lisdexamfetamine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000569	0.0018	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000567	0.00179	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000565	0.00179	CcSEcCtD
Lisdexamfetamine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000565	0.00179	CcSEcCtD
Lisdexamfetamine—Affect lability—Epirubicin—peripheral nervous system neoplasm	0.000562	0.00178	CcSEcCtD
Lisdexamfetamine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00056	0.00177	CcSEcCtD
Lisdexamfetamine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00056	0.00177	CcSEcCtD
Lisdexamfetamine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000559	0.00177	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000558	0.00176	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000554	0.00175	CcSEcCtD
Lisdexamfetamine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000553	0.00175	CcSEcCtD
Lisdexamfetamine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000549	0.00174	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000547	0.00173	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000547	0.00173	CcSEcCtD
Lisdexamfetamine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000543	0.00172	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.00054	0.00171	CcSEcCtD
Lisdexamfetamine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000538	0.0017	CcSEcCtD
Lisdexamfetamine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000538	0.0017	CcSEcCtD
Lisdexamfetamine—Rash—Topotecan—peripheral nervous system neoplasm	0.000538	0.0017	CcSEcCtD
Lisdexamfetamine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000538	0.0017	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000538	0.0017	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000536	0.0017	CcSEcCtD
Lisdexamfetamine—Headache—Topotecan—peripheral nervous system neoplasm	0.000535	0.00169	CcSEcCtD
Lisdexamfetamine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000534	0.00169	CcSEcCtD
Lisdexamfetamine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000534	0.00169	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000534	0.00169	CcSEcCtD
Lisdexamfetamine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000534	0.00169	CcSEcCtD
Lisdexamfetamine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000534	0.00169	CcSEcCtD
Lisdexamfetamine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000534	0.00169	CcSEcCtD
Lisdexamfetamine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000533	0.00169	CcSEcCtD
Lisdexamfetamine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000532	0.00168	CcSEcCtD
Lisdexamfetamine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000532	0.00168	CcSEcCtD
Lisdexamfetamine—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000531	0.00168	CcSEcCtD
Lisdexamfetamine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000531	0.00168	CcSEcCtD
Lisdexamfetamine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000531	0.00168	CcSEcCtD
Lisdexamfetamine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00053	0.00168	CcSEcCtD
Lisdexamfetamine—Constipation—Vincristine—peripheral nervous system neoplasm	0.000529	0.00167	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—peripheral nervous system neoplasm	0.000529	0.00167	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000529	0.00167	CcSEcCtD
Lisdexamfetamine—Rash—Melphalan—peripheral nervous system neoplasm	0.000527	0.00167	CcSEcCtD
Lisdexamfetamine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000527	0.00167	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000522	0.00165	CcSEcCtD
Lisdexamfetamine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000521	0.00165	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—peripheral nervous system neoplasm	0.00052	0.00165	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000519	0.00164	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000515	0.00163	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00051	0.00161	CcSEcCtD
Lisdexamfetamine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00051	0.00161	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000507	0.0016	CcSEcCtD
Lisdexamfetamine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000507	0.0016	CcSEcCtD
Lisdexamfetamine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000503	0.00159	CcSEcCtD
Lisdexamfetamine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000503	0.00159	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000501	0.00158	CcSEcCtD
Lisdexamfetamine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000497	0.00157	CcSEcCtD
Lisdexamfetamine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000497	0.00157	CcSEcCtD
Lisdexamfetamine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000489	0.00155	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000489	0.00155	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000488	0.00154	CcSEcCtD
Lisdexamfetamine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000487	0.00154	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000484	0.00153	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000483	0.00153	CcSEcCtD
Lisdexamfetamine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000478	0.00151	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000476	0.00151	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000475	0.0015	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000474	0.0015	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000473	0.0015	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000472	0.00149	CcSEcCtD
Lisdexamfetamine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000461	0.00146	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000456	0.00144	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000449	0.00142	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000447	0.00141	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000447	0.00141	CcSEcCtD
Lisdexamfetamine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000445	0.00141	CcSEcCtD
Lisdexamfetamine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000444	0.0014	CcSEcCtD
Lisdexamfetamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00044	0.00139	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000439	0.00139	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000437	0.00138	CcSEcCtD
Lisdexamfetamine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000436	0.00138	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000436	0.00138	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000433	0.00137	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000432	0.00137	CcSEcCtD
Lisdexamfetamine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000432	0.00137	CcSEcCtD
Lisdexamfetamine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000428	0.00135	CcSEcCtD
Lisdexamfetamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000424	0.00134	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000423	0.00134	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000416	0.00132	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000416	0.00132	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000413	0.00131	CcSEcCtD
Lisdexamfetamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000411	0.0013	CcSEcCtD
Lisdexamfetamine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000409	0.00129	CcSEcCtD
Lisdexamfetamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000408	0.00129	CcSEcCtD
Lisdexamfetamine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000405	0.00128	CcSEcCtD
Lisdexamfetamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000404	0.00128	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.00128	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000403	0.00127	CcSEcCtD
Lisdexamfetamine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000402	0.00127	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000398	0.00126	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000396	0.00125	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000395	0.00125	CcSEcCtD
Lisdexamfetamine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000393	0.00124	CcSEcCtD
Lisdexamfetamine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000392	0.00124	CcSEcCtD
Lisdexamfetamine—Rash—Vincristine—peripheral nervous system neoplasm	0.00039	0.00123	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00039	0.00123	CcSEcCtD
Lisdexamfetamine—Headache—Vincristine—peripheral nervous system neoplasm	0.000387	0.00123	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000385	0.00122	CcSEcCtD
Lisdexamfetamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000381	0.00121	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000381	0.0012	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000374	0.00118	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000374	0.00118	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000369	0.00117	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000369	0.00117	CcSEcCtD
Lisdexamfetamine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000367	0.00116	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000367	0.00116	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.00116	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000359	0.00114	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000357	0.00113	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000356	0.00113	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.00111	CcSEcCtD
Lisdexamfetamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000348	0.0011	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000346	0.0011	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.00109	CcSEcCtD
Lisdexamfetamine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000345	0.00109	CcSEcCtD
Lisdexamfetamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000344	0.00109	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000344	0.00109	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000343	0.00108	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000342	0.00108	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000339	0.00107	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000334	0.00106	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000331	0.00105	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.00104	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.00104	CcSEcCtD
Lisdexamfetamine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000325	0.00103	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000324	0.00103	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.00101	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000319	0.00101	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.00101	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000316	0.001	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—peripheral nervous system neoplasm	0.000316	0.000999	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000316	0.000998	CcSEcCtD
Lisdexamfetamine—Headache—Etoposide—peripheral nervous system neoplasm	0.000314	0.000993	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.000978	CcSEcCtD
Lisdexamfetamine—SLC18A2—ganglion—peripheral nervous system neoplasm	0.000309	0.194	CbGeAlD
Lisdexamfetamine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000304	0.000962	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000949	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000943	CcSEcCtD
Lisdexamfetamine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000298	0.000941	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000297	0.00094	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.000925	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000292	0.000923	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000291	0.00092	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000287	0.000906	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.00089	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000888	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000872	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000275	0.000871	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000869	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000274	0.000867	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000863	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000859	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.00027	0.000854	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000851	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000847	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000838	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000822	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000255	0.000806	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000803	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000254	0.000802	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000252	0.000798	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000794	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000792	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.00025	0.00079	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000783	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000782	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000772	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000767	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000766	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00024	0.00076	CcSEcCtD
Lisdexamfetamine—SLC6A3—nerve—peripheral nervous system neoplasm	0.000237	0.149	CbGeAlD
Lisdexamfetamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000743	CcSEcCtD
Lisdexamfetamine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.000234	0.147	CbGeAlD
Lisdexamfetamine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.000733	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000731	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000723	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000714	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000709	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000709	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000223	0.000706	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000703	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000702	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000654	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.000653	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.00065	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000637	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—PINK1—peripheral nervous system neoplasm	0.0002	0.143	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000608	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000605	CcSEcCtD
Lisdexamfetamine—SLC6A2—nerve—peripheral nervous system neoplasm	0.000191	0.12	CbGeAlD
Lisdexamfetamine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.000188	0.118	CbGeAlD
Lisdexamfetamine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.00059	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000186	0.000587	CcSEcCtD
Lisdexamfetamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000565	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000562	CcSEcCtD
Lisdexamfetamine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000177	0.00056	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000559	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000556	CcSEcCtD
Lisdexamfetamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.000543	CcSEcCtD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.000171	0.122	CbGpPWpGaD
Lisdexamfetamine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000528	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000523	CcSEcCtD
Lisdexamfetamine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000518	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000518	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000515	CcSEcCtD
Lisdexamfetamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000488	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.000148	0.106	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—brainstem—peripheral nervous system neoplasm	0.000134	0.0843	CbGeAlD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.000108	0.0771	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.000102	0.0638	CbGeAlD
Lisdexamfetamine—SLC6A2—brainstem—peripheral nervous system neoplasm	8.19e-05	0.0515	CbGeAlD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	8.1e-05	0.0579	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—cerebellum—peripheral nervous system neoplasm	6.62e-05	0.0416	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TH—peripheral nervous system neoplasm	5.17e-05	0.037	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—cerebellum—peripheral nervous system neoplasm	5.01e-05	0.0314	CbGeAlD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	4.83e-05	0.0345	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—TH—peripheral nervous system neoplasm	4.7e-05	0.0336	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TH—peripheral nervous system neoplasm	4.58e-05	0.0328	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—TH—peripheral nervous system neoplasm	4e-05	0.0286	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	2.02e-05	0.0145	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	1.89e-05	0.0135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	1.81e-05	0.0129	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—peripheral nervous system neoplasm	1.63e-05	0.0116	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	1.56e-05	0.0112	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	1.46e-05	0.0104	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BCHE—peripheral nervous system neoplasm	1.45e-05	0.0103	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.4e-05	0.01	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	1.38e-05	0.00988	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	1.34e-05	0.00957	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	1.19e-05	0.00855	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	1.13e-05	0.00805	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HGF—peripheral nervous system neoplasm	1.06e-05	0.00757	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	1.02e-05	0.00729	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	9.82e-06	0.00703	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	9.77e-06	0.00699	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	9.52e-06	0.00681	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	9.43e-06	0.00675	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—peripheral nervous system neoplasm	9.33e-06	0.00668	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	9.08e-06	0.0065	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	8.7e-06	0.00623	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	8.62e-06	0.00617	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	8.36e-06	0.00598	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	8.12e-06	0.00581	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.42e-06	0.00531	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	6.01e-06	0.0043	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.97e-06	0.00427	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.86e-06	0.00419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.76e-06	0.00412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—peripheral nervous system neoplasm	5.72e-06	0.00409	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—peripheral nervous system neoplasm	5.63e-06	0.00403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.23e-06	0.00374	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—peripheral nervous system neoplasm	5.05e-06	0.00362	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	5.01e-06	0.00359	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.99e-06	0.00357	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	4.93e-06	0.00353	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—peripheral nervous system neoplasm	4.76e-06	0.0034	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.58e-06	0.00328	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.43e-06	0.00317	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.42e-06	0.00316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.36e-06	0.00312	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.02e-06	0.00287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	4e-06	0.00286	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.96e-06	0.00284	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.94e-06	0.00282	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.66e-06	0.00262	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.56e-06	0.00255	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.49e-06	0.0025	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—peripheral nervous system neoplasm	3.39e-06	0.00243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.09e-06	0.00221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.97e-06	0.00212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.96e-06	0.00212	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.64e-06	0.00189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.59e-06	0.00185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.35e-06	0.00168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.34e-06	0.00168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.26e-06	0.00162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.17e-06	0.00155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.16e-06	0.00155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.05e-06	0.00147	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	2.02e-06	0.00145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.62e-06	0.00116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.43e-06	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.39e-06	0.000993	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.32e-06	0.000947	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.21e-06	0.000868	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.59e-07	0.000614	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.44e-07	0.000604	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.67e-07	0.000477	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.28e-07	0.000449	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.11e-07	0.000437	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.05e-07	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.55e-07	0.000397	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.07e-07	0.000363	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.72e-07	0.000338	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.88e-07	0.000278	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.71e-07	0.000265	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.28e-07	0.000234	CbGpPWpGaD
